Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations
| Condition | Advanced Malignant Solid Neoplasm, Glioblastoma, Recurrent Cholangiocarcinoma, Recurrent Glioma |
|---|---|
| Phase | Phase 2 |
| Sponsor | National Cancer Institute (NCI) |
| Status | Active, not recruiting |
| Enrollment | 89 participants |
| Interventions | Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib |
| Start date | Jan 30, 2019 |
| Completion date | Apr 2, 2025 |
| Results posted | Jun 17, 2026 |
Summary
This phase II trial studies how well olaparib works in treating patients with glioma, cholangiocarcinoma, or solid tumors with IDH1 or IDH2 mutations that has spread from where it first started (primary site) to other places in the body (metastatic) and that does not respond to treatment (refractory). Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Overall Response Rate
| Cohort 1A-Glioma Naïve to IDH I | 0 Participants |
|---|---|
| Cohort 1B- Glioma Pretreated | 0 Participants |
| Cohort 2A- Cholangio Naive | 0 Participants |
| Cohort 2B-Cholangio- Pretreated | 0 Participants |
| Cohort 3A Other -Naive | 0 Participants |
| Cohort 3B Other -Pretreated | 0 Participants |
Open in BENITIONS View on ClinicalTrials.gov
Other trials for this condition
- Solriamfetol in Improving Sleep in Patients With Grade II-IV Glioma — Wake Forest University Health Sciences
- Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblast — National Cancer Institute (NCI)
- TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma — National Cancer Institute (NCI)
- Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant G — City of Hope Medical Center
- Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma — L. Nicolas Gonzalez Castro, MD, PhD
- A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care — Bryan Allen